WO 2013/171642 PCT/IB2013/053771

[00369] The title compound was prepared in an analogous fashion to that described in Stage 22.1 using 5-bromo-6-chloro-N-(4-(chlorodifluoromethoxy)phenyl)nicotinamide (Stage 22.2) and 2-methylamino-ethanol to afford a white crystalline solid. HPLC (Condition 4)  $t_R = 5.72$  min, UPLC-MS (Condition 3)  $t_R = 1.14$  min, m/z = 452.2 [M+H]<sup>+</sup>.

#### Example 24

N-(4-(Chlorodifluoromethoxy ')phenvn-6-(ethyl(2-hvdroxyethyl ')amino')-5-(lH-pyrazol-5-vDnicotinamide

[00370] The title compound was prepared in an analogous fashion to that described in Example 26 using 5-bromo-N-(4-(chlorodifluoromethoxy)phenyl)-6-(ethyl(2-

hydroxyethyl)amino)nicotinamide (**Stage 24.1**) and l-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-lH-pyrazole to afford a yellow solid. UPLC-MS (Condition 3)  $t_R = 1.02$  min, m/z = 452.2 [M+H]+, m/z = 450.1 [M-H]-;  $^1$ H-N MR (400 MHz, DMSO-d<sub>6</sub>)  $\delta$  ppm 0.93 (t, J = 7.09 Hz, 3 H) 3.17 - 3.27 (m, 2 H) 3.35 - 3.43 (m, 2 H) 3.43 - 3.53 (m, 2 H) 4.59 (br. s, 1 H) 6.53 (d, J = 1.96 Hz, 1 H) 7.33 (d, J = 9.05 Hz, 2 H) 7.76 (br. s, 1 H) 7.82 - 7.95 (m, 2 H) 8.13 (d, J = 2.45 Hz, 1 H) 8.72 (d, J = 2.45 Hz, 1 H) 10.29 (s, 1 H) 12.98 (br. s, 1 H).

[00371] Stage 24.1 5-Bromo-N-(4-(chlorodifluoromethoxy)phenyl)-6-(ethyl(2-hydroxyethyl)amino)nicotinamide

[00372] The title compound was prepared in an analogous fashion to that described in Stage 22.1 using 5-bromo-6-chloro-N-(4-(chlorodifluoromethoxy)phenyl)nicotinamide (Stage

## Input image

## <image>\nParse the figure.


## <image>\n<|grounding|>Convert the document to markdown.

WO 2013/171642 PCT/IB2013/053771

[00369] The title compound was prepared in an analogous fashion to that described in Stage 22.1 using 5-bromo-6-chloro-N-(4-(chlorodifluoromethoxy)phenyl)nicotinamide (Stage 22.2) and 2-methylamino-ethanol to afford a white crystalline solid. HPLC (Condition 4) t<sub>R</sub> = 5.72 min, UPLC-MS (Condition 3) t<sub>R</sub> = 1.14 min, m/z = 452.2 [M+H]<sup>+</sup>.


#### Example 24

N-(4-(Chlorodifluoromethoxy ')phenvn-6-(ethyl(2-hvdroxyethyl ')amino')-5-(lH-pyrazol-5-vDnicotinamide



[00370] The title compound was prepared in an analogous fashion to that described in Example 26 using 5-bromo-N-(4-(chlorodifluoromethoxy)phenyl)-6-(ethyl(2-hydroxyethyl)amino)nicotinamide (Stage 24.1) and 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole to afford a yellow solid. UPLC-MS (Condition 3)  $t_R = 1.02 \text{ min}$ ,  $m/z = 452.2 \text{ [M+H]}^+$ ,  $m/z = 450.1 \text{ [M-H]}^-$ ;  $^1\text{H-NMR}$  (400 MHz, DMSO-d<sub>6</sub>)  $\delta$  ppm 0.93 (t, J = 7.09 Hz, 3 H) 3.17 - 3.27 (m, 2 H) 3.35 - 3.43 (m, 2 H) 3.43 - 3.53 (m, 2 H) 4.59 (br. s, 1 H) 6.53 (d, J = 1.96 Hz, 1 H) 7.33 (d, J = 9.05 Hz, 2 H) 7.76 (br. s, 1 H) 7.82 - 7.95 (m, 2 H) 8.13 (d, J = 2.45 Hz, 1 H) 8.72 (d, J = 2.45 Hz, 1 H) 10.29 (s, 1 H) 12.98 (br. s, 1 H).

[00371] Stage 24.1 5-Bromo-N-(4-(chlorodifluoromethoxy)phenyl)-6-(ethyl(2-hydroxyethyl)amino)nicotinamide



[00372] The title compound was prepared in an analogous fashion to that described in Stage 22.1 using 5-bromo-6-chloro-N-(4-(chlorodifluoromethoxy)phenyl)nicotinamide (Stage

### Result

[00369] The title compound was prepared in an analogous fashion to that described in Stage 22.1 using 5-bromo- 6- chloro- N- (4- (chlorodifluoromethoxy)phenyl)nicotinamide (Stage 22.2) and 2- methylamino- ethanol to afford a white crystalline solid. HPLC (Condition 4)  $t_{\rm R}=5.72$  min, UPLC- MS (Condition 3)  $t_{\rm R}=1.14{\rm min}, {\rm m/z}=452.2[{\rm M}+{\rm H}]^+$ .

#### Example 24

N- (4- (Chlorodifluoromethoxy)phenvn- 6- (ethyl(2- hvdroxyethyl)amino)- 5- (IH- pyrazol- 5- vDnicotinamide

[00370] The title compound was prepared in an analogous fashion to that described in Example 26 using 5-bromo- N- (4- (chlorodifluoromethoxy)phenyl)- 6- (ethyl(2- hydroxyethyl)amino)nicotinamide (Stage 24.1) and 1- (tetrahydro- 2H- pyran- 2- yl)- 5- (4,4,5,5- tetramethyl- 1,3,2- dioxaborolan- 2- yl)- 1H- pyrazole to afford a yellow solid. UPLC- MS (Condition 3)

 $t_R=1.02 min, m/z=452.2 [M+H]^+, m/z=450.1 [M-H]^-; ^1H-NMR \ (400 \ MHz, DMSO- \ d6) \ \delta \ ppm \\ 0.93 \ (t, J=7.09 Hz, 3H) \ 3.17 - 3.27 \ (m, 2 \ H) \ 3.35 - 3.43 \ (m, 2 \ H) \ 3.43 - 3.53 \ (m, 2 \ H) \ 4.59 \ (br. \ s, 1 \ H) \ 6.53 \ (d, J=1.96 Hz, 1H) \ 7.33 \ (d, J=9.05 Hz, 2H) \ 7.76 \ (br. \ s, 1 \ H) \ 7.82 - 7.95 \ (m, 2 \ H) \ 8.13 \ (d, J=2.45 Hz, 1H) \ 8.72 \ (d, J=2.45 Hz, 1H) \ 10.29 \ (s, 1 \ H) \ 12.98 \ (br. \ s, 1 \ H).$ 

[00371] Stage 24.1 5- Bromo- N- (4- (chlorodifluoromethoxy)phenyl)- 6- (ethyl(2-hydroxyethyl)amino)nicotinamide

[00372] The title compound was prepared in an analogous fashion to that described in Stage 22.1 using 5-bromo- 6-chloro- N- (4- (chlorodifluoromethoxy)phenyl)nicotinamide (Stage

# Rendering